How Mycosis Fungoides Medications Work

Mycosis fungoides is a type of cutaneous T-cell lymphoma (CTCL) characterized by skin lesions and patches. The goal of treatment is to control the disease, alleviate symptoms, and improve quality of life.

Gold Standard Treatment: Methotrexate

• Methotrexate works by inhibiting dihydrofolate reductase (DHFR), an enzyme essential for DNA synthesis and cell division. This leads to the death of rapidly dividing cancer cells, including those responsible for mycosis fungoides.
• As a chemotherapeutic agent, methotrexate is effective in controlling skin lesions and symptoms such as itching and fatigue.

Alternative Treatments

• Bexarotene: A retinoid derivative that targets the nuclear receptor peroxisome proliferator-activated receptor (PPAR) gamma. Bexarotene induces apoptosis in cancer cells and has been shown to be effective in treating mycosis fungoides.
• Denileukin diftitox: A fusion protein composed of interleukin-2 (IL-2) and diphtheria toxin. It works by binding to IL-2 receptors on T-cells, leading to cell death.
• Alemtuzumab: A monoclonal antibody targeting CD52, a protein present on the surface of mature lymphocytes. Alemtuzumab depletes lymphocytes, including those responsible for mycosis fungoides.

These alternative treatments offer options for patients who do not respond to methotrexate or experience adverse effects. The choice of treatment depends on individual patient factors and disease characteristics.